NICE Guideline CG61 on Hypnotherapy for IBS: What the UK Actually Recommends (Honest Breakdown)

Why NICE matters (and what 'CG61' actually means for clinical decision-making)

The National Institute for Health and Care Excellence is the body that produces clinical guidelines for the UK National Health Service. NICE guidelines are not laws and they are not regulations. They are evidence-graded recommendations that NHS clinicians are expected to consider when making treatment decisions, and that NHS commissioners use when deciding what to fund. A NICE recommendation does not mean every NHS patient receives the recommended intervention. It means the recommendation has been through a defined evidence review process and has been judged to be supported by enough evidence to enter formal clinical guidance.

NICE Clinical Guideline CG61 is titled 'Irritable bowel syndrome in adults: diagnosis and management'. It was originally published in February 2008 and last updated in April 2017. The full guideline covers diagnosis, dietary advice, pharmacological treatment, psychological intervention, and follow-up. The psychological intervention section is where the hypnotherapy recommendation lives.

Why this matters for a Canadian patient or clinician, even though Canada has its own health system. First, NICE guidelines are widely referenced internationally because the evidence review process is rigorous and the wording is precise. A NICE recommendation is treated as a credible institutional endorsement in conversations well beyond the UK. Second, the underlying RCT evidence that NICE CG61 reviewed is the same evidence that informs guidelines in other countries (it is the same global literature). Third, Canadian gastroenterology practice draws heavily on both UK and US guideline frameworks. A Canadian GI who is familiar with the IBS literature is very likely familiar with NICE CG61 even if they do not practice in the NHS.

What 'CG61' specifically tells you about the guideline. The CG prefix means Clinical Guideline. The 61 is the sequential identifier. NICE has hundreds of CGs covering different conditions. CG61 is the IBS guideline. If you want to verify any claim about what NICE says about IBS hypnotherapy, you go to the NICE website, search for CG61, and read the relevant numbered recommendation directly. The current version of CG61 is freely available on nice.org.uk.

The specific recommendation that mentions hypnotherapy is recommendation 1.4.2 in the psychological interventions section. The numbering matters because anyone quoting NICE on hypnotherapy for IBS should be able to point you to the specific numbered recommendation in the specific guideline. 'NICE recommends hypnotherapy for IBS' without the CG61 reference and without the recommendation number is a paraphrase. The accurate citation lets a reader verify the claim themselves.

What the guideline actually says about hypnotherapy (verbatim citation plus plain English)

Here is the part of NICE CG61 that matters. The exact wording in recommendation 1.4.2 of the published guideline says (paraphrased here to stay under 15 words verbatim quotation): for people whose IBS symptoms do not respond to pharmacological treatments after 12 months and who develop a continuing symptom profile (described in the guideline as refractory IBS), NICE recommends considering referral for psychological intervention. The guideline explicitly names three categories of psychological intervention worth considering: cognitive behavioural therapy (CBT), hypnotherapy, and psychological therapy.

In plain English, what that recommendation tells a clinician is this. If a patient has had IBS symptoms for at least 12 months, and the patient has tried the standard pharmacological treatments at the doses and durations the rest of CG61 specifies, and the patient still has a continuing symptom profile that meets the refractory definition, the clinician should consider referring the patient for one of three categories of psychological intervention. Hypnotherapy is one of those three categories. CBT is another. The third is described in the guideline as 'psychological therapy' (which in the broader literature covers gut-directed psychotherapies like brief dynamic therapy, mindfulness-based interventions, and other structured psychological treatments studied for IBS).

Three details about the wording that are easy to miss.

First, the recommendation says 'consider'. NICE uses a graded vocabulary for the strength of its recommendations. 'Offer' is the strongest level. 'Consider' is the next level down. A 'consider' recommendation is a real recommendation, not a passing mention, but it is also not as strong as an 'offer' recommendation. The clinician is expected to weigh the recommendation against the patient's specific situation and preferences rather than apply it routinely.

Second, the recommendation puts hypnotherapy in the same tier as CBT. This matters because CBT is well-recognized as a psychological treatment for IBS with substantial RCT support. NICE did not place hypnotherapy in a separate, weaker tier. The three options sit in the same recommendation.

Third, the recommendation is for referral. NICE CG61 does not specify the protocol, the number of sessions, or the credentialing requirements for the hypnotherapist. Those decisions are left to the referring clinician and the local availability of services. In the UK that means NHS-affiliated psychology services or specialist hypnotherapy services. In Canada the equivalent is the local availability of trained gut-directed hypnotherapy practitioners (see the flagship evidence review for how to think about practitioner selection given that hypnotherapy is not a regulated profession in Alberta).

The practical upshot of the verbatim wording: NICE CG61 puts hypnotherapy in the same tier as CBT, conditionally recommends it for patients in the refractory IBS subgroup, and leaves the implementation details to the referring clinician. That is the actual recommendation. It is a real endorsement. It is not a blanket recommendation for everyone with IBS.

What 'refractory IBS' means in the NICE recommendation (you might or might not qualify)

The single most consequential word in recommendation 1.4.2 is 'refractory'. The NICE recommendation for psychological intervention (including hypnotherapy) is specifically for patients with refractory IBS, not for patients with newly diagnosed or shorter-duration IBS. If you are deciding whether the NICE recommendation applies to you, you need to know what NICE means by refractory.

The NICE CG61 definition of refractory IBS has two components.

First, duration. The symptoms have continued for at least 12 months. NICE chose 12 months because the natural course of IBS includes spontaneous fluctuation, and the response to first-line interventions cannot be fully assessed in a few weeks. A 12-month minimum filters out patients whose symptoms might resolve on their own or who have not yet had adequate time to evaluate first-line treatments.

Second, inadequate response to first-line pharmacological treatment. The rest of NICE CG61 specifies what first-line pharmacological treatment looks like. For IBS-C (constipation-predominant) the first-line options include laxatives (with linaclotide considered if conventional laxatives have failed). For IBS-D (diarrhoea-predominant) the first-line options include loperamide. For pain and bloating the first-line options include antispasmodics (mebeverine, peppermint oil, hyoscine). For patients whose symptoms persist despite first-line options, tricyclic antidepressants are considered as a second-line pharmacological option (low-dose amitriptyline is the most commonly referenced).

Refractory in the NICE sense means: you have tried the first-line pharmacological options for your IBS subtype, you have tried them for long enough at appropriate doses to evaluate response, your symptoms have continued at a level that is meaningfully impacting your quality of life, and you have had the symptoms for at least 12 months in total. If all three conditions are true, you are in the patient group that recommendation 1.4.2 is talking about.

What this means for you specifically.

If you are within 12 months of your IBS diagnosis and you have not yet tried first-line options, the NICE recommendation does not directly apply to your situation yet. It might apply later if your symptoms persist after a year of first-line treatment. In the meantime, the recommendation does not block you from trying hypnotherapy; it just means NICE has not made a guideline-level recommendation for that decision.

If you are past 12 months of symptoms, you have tried first-line pharmacological options at adequate doses and durations, and your symptoms continue to impact your life, you are exactly the patient NICE CG61 is talking about. You are in the recommendation. Recommendation 1.4.2 is the guideline-level endorsement of psychological intervention (including hypnotherapy) for your situation.

If you are past 12 months but you have not tried first-line pharmacological options (whether because of contraindications, side effect intolerance, or personal preference), the NICE recommendation is technically silent on your situation. The recommendation assumes the first-line options have been tried. A defensible reading is that hypnotherapy is still a reasonable option for patients who cannot or will not take first-line pharmacological treatments, but that read goes beyond the strict letter of the recommendation.

The honest summary: 'NICE recommends hypnotherapy for IBS' is true, with the qualifier that the recommendation is for the refractory subgroup as NICE defines it. If you are in that subgroup, the recommendation is directly relevant to your situation. If you are not yet in that subgroup, the recommendation is part of the longer-term decision landscape but does not directly apply to your current situation.

How this compares to Canadian and American guidelines (ACG 2021, Canadian Association of Gastroenterology)

NICE CG61 is the most-cited guideline-level recommendation for IBS hypnotherapy globally, but it is not the only one. Two other guideline frameworks matter for Canadian patients.

The American College of Gastroenterology (ACG) 2021 IBS guideline. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021;116(1):17-44. This is the most recent comprehensive North American guideline for IBS management. The ACG 2021 guideline addresses gut-directed psychotherapies (a broader category that includes gut-directed CBT and gut-directed hypnotherapy) and makes a conditional recommendation that these therapies be used for treatment of global IBS symptoms in patients who have not responded to first-line therapy. The ACG used the GRADE methodology for evidence grading. They classified the supporting evidence as moderate quality and the recommendation as conditional.

What this means in practical terms for a Canadian patient: the ACG guideline reaches a substantially similar conclusion to NICE CG61. The patient population is described slightly differently (ACG says 'not responded to first-line therapy', NICE says 'refractory after 12 months of first-line treatment'), but the underlying clinical situation is the same. Both guidelines place gut-directed psychological therapies (including hypnotherapy) in the toolkit for patients whose IBS has not responded adequately to standard first-line care. Both recommendations are conditional rather than strong.

The Canadian Association of Gastroenterology (CAG). The CAG has issued consensus statements on IBS management that acknowledge psychological therapies as part of the management toolkit, but the CAG has not issued a guideline of the same comprehensive scope as NICE CG61 or ACG 2021 specifically for gut-directed psychotherapies as standalone interventions. The closest CAG document is the CAG IBS clinical practice guideline (Moayyedi et al, J Can Assoc Gastroenterol). This document covers diagnosis, dietary advice, and pharmacological treatment in depth, and acknowledges psychological therapies as a part of the management approach without going to the same level of specific recommendation as NICE or ACG.

The practical upshot for a Canadian patient or clinician: the most-cited guideline-level recommendations for gut-directed psychological therapies (including hypnotherapy) in IBS are NICE CG61 (2008, updated 2017) and ACG 2021. Both are conditional recommendations for patients who have not responded to first-line care. The Canadian guideline landscape has not issued a recommendation of the same specific scope but it does not contradict the NICE and ACG positions. A Canadian GP or GI who wants to verify the international guideline position has both NICE CG61 and ACG 2021 as direct references.

For the underlying RCT evidence that all three guideline frameworks draw on, see the flagship evidence review, which walks through Whorwell 1984 (The Lancet, the foundational protocol), Moser 2013 (Am J Gastroenterol, the long-horizon durability trial), Gonsalkorale 2003 (Gut, the largest clinical audit), and Peters 2016 (Aliment Pharmacol Ther, the head-to-head versus low-FODMAP). For the Peters 2016 single-trial deep dive specifically, see the Peters 2016 RCT breakdown.

Why most patients and GPs do not know about this recommendation (the awareness gap)

The most common reaction I see from patients and from GPs when the NICE CG61 hypnotherapy recommendation comes up is mild surprise. Patients say 'I have had IBS for 8 years and no one has ever mentioned this to me.' GPs say 'I have not looked at the IBS guideline in detail in several years and I did not realize that was in there.' Both reactions are understandable and they point to the same underlying gap.

Why the gap exists.

Reason one: the recommendation is buried in a long guideline. NICE CG61 is a comprehensive document covering diagnosis, dietary advice, pharmacological treatment, follow-up, and psychological intervention. The psychological intervention section is one section among many. A GP reading the guideline for IBS management is mostly using it to confirm first-line pharmacological choices. The psychological intervention recommendation is in the part of the guideline that gets less attention because it applies to a smaller patient subgroup.

Reason two: referral pathways are not well-developed. NICE recommends referral for psychological intervention but does not specify where the patient should be referred to or how that referral should be funded. In the UK NHS context the referral typically goes to gut-directed CBT services where they exist (which is not all NHS trusts) or to specialist hypnotherapy services where they exist (which is also not all NHS trusts). In Canada there is no equivalent pathway. A Canadian GP who wants to refer a patient for gut-directed hypnotherapy is doing it without an established referral infrastructure. The lack of pathway makes the recommendation feel more theoretical than practical.

Reason three: hypnotherapy carries unhelpful cultural baggage. Stage hypnotism, mass-media depictions, and the lack of regulation in many jurisdictions all conspire to make hypnotherapy sound less serious than it is in a clinical context. A clinician who hears 'hypnotherapy' may default to the stage-hypnotism mental model rather than the gut-directed clinical protocol mental model (the latter is what NICE actually recommends). The mental-model mismatch creates a barrier even when the recommendation is known.

Reason four: medical education does not consistently cover psychological IBS interventions. Family medicine residency curricula in Canada cover IBS but tend to emphasize diagnostic criteria, red flags, and pharmacological management. The psychological intervention literature gets less curricular time. A GP who completed residency more than a few years ago may not have encountered the gut-directed psychotherapy evidence base in formal training.

Reason five: there is no industry pushing the message. Pharmaceutical companies promote pharmacological treatments. Diet industry actors promote dietary approaches. Gut-directed hypnotherapy has no industry sponsor with a marketing budget. The recommendation exists but no one is making sure clinicians and patients hear about it. The information gap is not malicious, it is just unfilled.

What the awareness gap means for you.

If you are a patient and your GP does not know about the NICE CG61 hypnotherapy recommendation, that is not evidence that the recommendation does not exist or that your GP is uninformed. It is evidence that the recommendation has not been actively promoted to clinicians the way other treatment options have. You can fill the gap by bringing the citation to the conversation. The next section gives you the exact wording.

If you are a clinician who is hearing about the recommendation for the first time, the source is recommendation 1.4.2 of NICE CG61 (Irritable bowel syndrome in adults: diagnosis and management, first issued 2008, last updated 2017). The full guideline is freely available on nice.org.uk. The parallel American recommendation is in ACG 2021 (Lacy et al, Am J Gastroenterol 2021;116(1):17-44). Both are credible institutional references for a refractory IBS treatment discussion.

How to use this when talking to your GP or GI (script plus research to bring)

If you have decided that you want to discuss the NICE CG61 recommendation with your GP or your gastroenterologist, the conversation goes better when it is framed as a guideline question rather than as a request for a specific treatment. Clinicians respond well to evidence-based requests; they respond less well to requests that feel like patient self-prescription. Here is a script that respects the clinician's frame and uses the NICE recommendation accurately.

Opening sentence. 'I have been reading about treatment options for my IBS, and I came across NICE Clinical Guideline CG61 on IBS management. Recommendation 1.4.2 in that guideline recommends considering referral for psychological intervention, including hypnotherapy, for patients whose symptoms have continued for at least 12 months despite first-line treatment. I think I am in that group. I would like to discuss whether referral for gut-directed hypnotherapy might be appropriate for me.'

This opening does four things at once. It cites the specific guideline. It uses the technical language ('refractory', '12 months', 'first-line treatment') the clinician will recognize. It positions the patient as someone who has read the guideline rather than someone who has Googled a treatment. It asks for a discussion rather than demanding a prescription.

If the clinician is not familiar with the recommendation. This will happen sometimes. The response that works is to offer to email the citation. 'I have a link to the full guideline if it would help. The recommendation is at nice.org.uk under CG61, section 1.4.2.' Most clinicians will look it up either during the visit or afterward.

If the clinician is familiar with the recommendation but uncertain about local availability. This is the most common scenario in Canada. The response that works is to acknowledge the implementation gap and offer to do the legwork. 'I understand there is not a formal NHS-style referral pathway for this in Alberta. I have been looking into ARCH-credentialed gut-directed hypnotherapy practitioners. Would you be open to writing a referral letter or recommendation that I can take to a practitioner for my records?'

If the clinician suggests CBT instead. CBT is in the same NICE recommendation tier as hypnotherapy. CBT has a larger evidence base in the gut-directed psychological intervention literature overall. A CBT recommendation is consistent with NICE CG61. The response that works is to acknowledge the option and ask about access. 'CBT is also in the NICE recommendation. Are there gut-directed CBT services available locally that I could be referred to?' If the answer is no (which is often the case in Canada), gut-directed hypnotherapy is the available option in the same recommendation tier.

Research to bring to the appointment. A one-page printout with the following helps the conversation: the NICE CG61 citation with the recommendation number (1.4.2), the ACG 2021 citation (Lacy et al, Am J Gastroenterol 2021;116(1):17-44) so the clinician has the parallel American guideline reference, a one-sentence summary of the underlying foundational trial (Whorwell, Prior, and Faragher 1984 in The Lancet established the gut-directed hypnotherapy protocol in severe refractory IBS), and a one-sentence summary of the most recent durability trial (Moser et al 2013 in Am J Gastroenterol showed 54 percent of hypnotherapy patients maintained the responder threshold at 15 months versus 25 percent of controls).

What not to ask for. Do not ask the clinician to certify that gut-directed hypnotherapy will work for you. They cannot, no one can. The evidence base supports the recommendation for the patient group; individual response varies. Do not ask the clinician to bill OHIP or AHCIP for a hypnotherapy visit. They cannot, because hypnotherapy is not a covered service. Do not ask the clinician to refer you to a specific practitioner by name. Most clinicians will not name a specific private practitioner because of professional conventions; a general recommendation that you pursue gut-directed hypnotherapy with an appropriately credentialed practitioner is what you can reasonably ask for.

For cost and insurance reality in Canada, here is the honest version. At Calgary Gut Hypnotherapy, sessions are $220 to $350 depending on complexity, with a 3-session minimum commitment ($660 to $1,050) and a full protocol typically running 6 to 8 sessions ($1,320 to $2,800). Hypnotherapy isn't directly covered by Canadian provincial health plans or most extended health benefit plans. Hypnotherapy isn't a regulated profession in Alberta. Some clients get reimbursement through their employer's Wellness Spending Account (WSA) under categories like 'stress management' or 'mental wellness'. WSAs are different from Health Spending Accounts (HSAs), which follow strict CRA medical-expense rules that exclude practitioners who aren't on a provincial regulated list. Always check with your specific plan whether RCH services qualify.

For credentialing in an unregulated field: ARCH (Association of Registered Clinical Hypnotherapists of Canada) is Canada's most stringent voluntary professional body for clinical hypnotherapy. A practitioner who is ARCH-credentialed, works from a named protocol (Manchester or North Carolina), and publishes pricing transparently is the high end of the Canadian distribution. The NICE recommendation is for the protocol, not for general hypnotic technique. Make sure the practitioner you book is delivering the protocol the recommendation refers to.